Abstract
Patients with chronic hepatitis B treated with chemotherapy or immunotherapy are at risk of viral reactivation, which can have serious or even fatal consequences [1]. Patients treated with chemotherapy for haematological disease have a known risk of hepatitis B virus (HBV) reactivation with an estimated incidence of 14-72% [2]. The majority of chemotherapy drugs can induce HBV reactivation in patients with HBs-positive antigen [3]. HBs testing should therefore be recommended prior to chemotherapy. Preventive antiviral treatment will reduce the risk of HBV reactivation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
